malondialdehyde has been researched along with Fabry Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barschak, AG; Biancini, GB; Deon, M; Giugliani, R; Jardim, LB; Manfredini, V; Netto, CB; Ribas, GS; Rodrigues, DB; Vanzin, CS; Vargas, CR | 1 |
1 other study(ies) available for malondialdehyde and Fabry Disease
| Article | Year |
|---|---|
Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy.
Topics: Adult; alpha-Galactosidase; Antioxidants; Catalase; Enzyme Replacement Therapy; Erythrocytes; Fabry Disease; Female; Glutathione; Glutathione Peroxidase; Humans; Inflammation; Interleukin-6; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Reactive Oxygen Species; Superoxide Dismutase; Trihexosylceramides; Tumor Necrosis Factor-alpha; Tyrosine; Young Adult | 2012 |